Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05211323
Title A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

hepatocellular carcinoma

liver carcinoma

cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine

Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.